Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Sten Stovall
Duo to equally share development costs and profits from any candidates emerging from their RNAi discovery pact.
Early results confirm dasiglucagon's safety profile with no treatment-induced or treatment-boosted anti-drug antibodies.
Roche is "first to market" with Phase III Tecentriq data in first-line squamous NSCLC setting, but analysts note Merck and Bristol are not far behind.
Alzheon tells prospective investors it believes beta-amyloid blocker ALZ-801 can succeed in pivotal trials by treating APOE4 subgroup.
Arix Bioscience's £87m equity raising brings to £250m the amount it has raised for incubating life sciences start-ups – but it might be the last for a while if portfolio 'exits' start generating cash, its CEO tells Scrip.
Diurnal's CEO Martin Whitaker says 2018 promises to be transformational for the late-stage endocrinology company.